PhaseBio Pharmaceuticals — Investor Presentation (August 2021)
34 slides from PhaseBio Pharmaceuticals's investor presentation, Aug 12, 2021
Slide 1: Corporate Overview August 2021
Corporate Overview August 2021
Slide 2: Forward-looking statements
This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str
Slide 3: Therapeutic Focus
Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiopulmonary diseases Product Candidates Bentracimab (PB2452) Novel agent in Phase 3 development for immediate and sustained reversal of ticagrelor, the preferred antipl
Slide 4: Pipeline programs and upcoming milestone targets
Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity Q4 2021 Topline results from Interim Analysis of REVERSE-IT and Phase 2b trial of bentracimab Pemziviptadil Pulmonary Arterial Hypertension (PAH) Mid 202
Slide 5: Corporate
) Corporate
Slide 6: Experienced Management Team
6 Experienced Management Team JONATHAN MOW Chief Executive Officer SUSAN ARNOLD, PhD VP of Preclinical & CMC GLEN BURKHARDT VP Human Resources KRIS HANSON VP Legal JOHN LEE, MD, PhD, FACC Chief Medical Officer JOHN SHARP Chief Financial Officer MICHAEL YORK VP Corp Development & Commercial Strategy
Slide 7: 2020 Was A Year of Substantial Progress
• Rapid pace of development and execution in 2020, sets the stage for success in 2021 Announced innovative funding and co-development collaboration for bentracimab with SFJ Pharmaceuticals Bolstered pipeline with acquisition of resistant hypertension asset, PB6440 Granted EMA PRIME designation
Slide 8: Q2 2021 Financial Highlights
• Sublicense revenue*: $10.3M • Operating expense: $31.4M ⎯ R&D: $27.4M ⎯ SG&A: $4.0M • Loss from Operations: ($21.1M) • Net Loss of ($28.7M) or ($0.60) per share, basic and diluted ⎯ 48.0M shares used for computing Q2 2021 net loss per share • Cash and cash equivalents as of 06/3/2021: $64.5M ⎯ Cas
Slide 9: Bentracimab (PB2452) Reversal Agent for Ticagrelor
Bentracimab (PB2452) Reversal Agent for Ticagrelor
Slide 10: Bentracimab urgent surgery or intervention
Bentracimab 10 URGENT SURGERY OR INTERVENTION • Currently oral P2Y12 agents, including ticagrelor, require a 5-day washout prior to surgery1,2 ⎯ Urgent surgery often cannot wait 5 days ⎯ Higher thrombotic risk during washout • In Phase 1 and Phase 2a studies, bentracimab observed to immediately and
Slide 11: Well-Characterized Mechanism of Reversal of Ticagrelor
BentracimabBentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor 11 1. 2. 3. 4. 5. 6. ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation Bentracimab binds to free ticagrelor with very high affinity This is a r
Slide 12: Phase 1 Proof-of-Concept Study in Healthy Subjects
Bentracimab Bentracimab Phase 1 Proof-of-Concept Study in Healthy Subjects • Randomized, double-blind, placebo-controlled, single ascending dose, sequential group study (n=64) • Platelet function evaluated using three well established and commonly used assays: LTA, VerifyNow PRUTest® and VASP ⎯ Resu
Slide 13: Normalized Platelet Function After Ticagrelor Reversal
Bentracimab Dose-dependent response across all cohorts tested Immediate reversal within 5 minutes of start of infusion Sustained duration of reversal extended to 20+ hours Enables rapid resumption of ticagrelor dosing post infusion Well tolerated across all cohorts No drug-related SAEs r
Slide 14: Positive Preliminary Bentracimab Phase 2a Results
Bentracimab Positive Preliminary Bentracimab Phase 2a Results • Positive preliminary results from the bentracimab Phase 2a trial were disclosed via press release1 ⎯ First trial of bentracimab to include older and elderly subjects (ages 50-80) on dual antiplatelet therapy (DAPT) of ticagrelor and low
Slide 15: REVERSE-IT: Pivotal Phase 3 Trial Overview
Bentracimab REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview • REVERSE-IT: Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial • Phase 3 trial is a key element of development plan that has garnered FDA Breakthrough Therapy and EMA PRIME designations • Open-label, single-arm study o
Slide 16: REVERSE-IT Enrollment for Interim Analysis Complete
bentracimab REVERSE-IT Enrollment for Interim Analysis Complete 16 As of August 9, 2021, REVERSE-IT had enrolled 143 patients for the Interim Analysis • Enrollment includes 138 patients requiring urgent surgery and five patients with uncontrolled major bleeding • Surgery cohort enrollment complete;
Slide 17: REVERSE-IT Predominance of Surgical Patients
bentracimab REVERSE-IT Predominance of Surgical Patients 17 Pandemic impact on bleeding patient admissions • Reduction in hospital admissions for major adverse spontaneous events like bleeding • Broad, global moratorium on clinical research and furloughs of research staff • Smaller REVERSE-IT footpr
Slide 18: Revised Timelines of Bentracimab Program
bentracimab Revised Timelines of Bentracimab Program 18 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteersPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive PB2452 N=143, major bleeding + urgent surgery patients Final N=200 Post -a
Slide 19: EMA and FDA regulatory interactions
bentracimab EMA: • Scientific Advice ⎯ Face-to-face interaction and written guidance in general agreement with proposed development plan for bentracimab • PRIME designation1 ⎯ Granted to support medicines that demonstrate the potential to address substantial unmet medical need ⎯ Potentially expedite
Slide 20: Expect Continued Long-Term Rx Growth of Ticagrelor
Bentracimab Expect Continued Long-Term Rx Growth of Ticagrelor Bentracimab approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2020 were $1.6B and growing ⎯ Pandemic impact dampened 2020 growth ⎯ Patient growth remains a key driver of Y/Y revenue growth in ke
Slide 21: Bleeding Events in P2Y12-Treated Medicare Patients
Bleeding Events in P2Y12-Treated Medicare Patients Occur More Frequently than FXa-Treated Medicare Patients 21 P2Y12 Class Bleeds Are More Common than FXa Class Bleeds Comparison of P2Y12 and FXa class Bleeding Data (rate per 100 person-years All P2Y12 All FXa % diff P2Y12/FXa p-value P2Y12 vs. FXa
Slide 22: P2Y12 Class Inpatient Admissions for Bleeding and Surgery
P2Y12 Class Inpatient Admissions for Bleeding and Surgery 22 Estimates of Bleeding and Surgery Events in P2Y12 Patients While Persistent1 2019 P2Y12 Patients: 4.46m2 Commercial Medicare Medicaid Totals Rate per 100 person-years N3 Rate per 100 person-years N3 Rate per 100 person-years N3 Any Bleedin
Slide 23: Lipitor Analog Points to Potential Ticagrelor Share Increase
Lipitor Analog Points to Potential ~2.5X Increase in Post-LOE Ticagrelor Market Share Within the P2Y12 Inhibitor Class 23 51.1% 0% 10% 20% 30% 40% 50% 60% M ol ec ul e St an da rd U ni ts S ha re Atorvastatin/Lipitor Fluvastatin/Lescol Lovastatin/Altoprev Pitavastatin/Livalo Pravastatin/Pravachol Ro
Slide 24: Alfasigma Licensing Agreement
Alfasigma S.p.A Licensing Agreement: Unlocking the Potential of Bentracimab in Europe and Beyond 24 • 49 countries in the EU, EEA, Russia and CIS • $20 million upfront • $35 million potential pre-revenue regulatory milestones • Up to $190 million in sales milestones • Double digit net sales royaltie
Slide 25: SFJ Pharmaceuticals Funding and Co-Development Collaboration
Bentracimab SFJ Pharmaceuticals Funding and Co-Development Collaboration • Innovative collaboration between SFJ and PhaseBio to support the global development of bentracimab • SFJ will fund up to $120 million to support the clinical development of bentracimab ⎯ SFJ has extensive experience in the gl
Slide 26: Pemziviptadil (PB1046) Once Weekly VIP Analog
Pemziviptadil (PB1046) Once Weekly Vasoactive Intestinal Peptide (VIP) Analog
Slide 27: Harnessing VIP to Create a Stable, Long-Acting Drug
Pemziviptadil PRECLINICAL STUDIES Support Clinical Development for: • Pulmonary Arterial Hypertension • DMD Cardiomyopathy • Heart Failure (Chemotherapy-Induced HF or HFpEF) • Cystic Fibrosis MECHANISM OF ACTION VIA VPAC2 RECEPTOR • Potent vasodilator and immunomodulator • Anti-inflammatory and anti
Slide 28: Proprietary Elastin-Like Polypeptide (ELP) Technology
Pemziviptadil PROLONGED CIRCULATING HALF-LIFE COACERVATION DELIVERS SLOW RELEASE Proprietary Elastin-Like Polypeptide (ELP) Technology Key to optimizing the profile of an injectable VIP product candidate 28 Repeating Sequence of Human Elastin Peptides VPGXG Peptide/Protein (VIP, GLP1, etc.) Active M
Slide 29: High Unmet Need in an Orphan Disease
Pemziviptadil High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) • High unmet need for novel disease-modifying PAH therapies for greater efficacy ⎯ All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways
Slide 30: Clinical Development Activities to Date
PemziviptadilPemziviptadil Clinical Development Activities to Date Have Supported Advancement into Phase 2 Efficacy Studies 30 PHASE 1 Studies Completed PHASE 2 PAH Studies • Well tolerated for a week over broad range of exposure; no drug-related SAEs reported • Prolonged PK/PD profile over 1 week •
Slide 31: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
Slide 32: PB6440 for Resistant Hypertension
PB6440 PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensive
Slide 33: PB6440 Highly Selective for Aldosterone Synthase
PB6440 CYP11B Potency and Selectivity (IC50, µM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699* 0.0007 0.013 19 0.016 0.059 3.7 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in
Slide 34: PhaseBio
PhaseBio
PhaseBio Pharmaceuticals — Investor Presentation (August 2021) on 6ix